Patents Examined by Carlos A. Azpuru
  • Patent number: 11969510
    Abstract: A chitosan film including ternary metal oxides. In an embodiment, the ternary metal oxides can include tungsten oxide nanoparticles (WO3 NPs), magnesium oxide nanoparticles (MgO NPs), and a graphene oxide (GO) layer. In an embodiment the chitosan film is porous. The chitosan film including ternary metal oxides can be used as a wound dressing for the clinical management of bacterially infected wounds.
    Type: Grant
    Filed: December 7, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mohamed Gouda, Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed
  • Patent number: 11969398
    Abstract: This invention discloses methods and composition to form biodegradable polymer implant arrays in the live tissue. Artificial cavities are created in the live tissue by using laser ablation, oscillating needle, microneedle array and other methods. The cavities are then filled with biodegradable polymer solution. The solvent in the polymer solution is dissipated in the tissue to form a biodegradable polymer implant in artificial cavities. The cavities and implants formed are arranged to form of an array of implants. The biodegradable polymer in the cavity can also be loaded with drug to form biodegradable drug delivery array in the live tissue.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: April 30, 2024
    Assignee: PATHAK HOLDINGS LLC
    Inventor: Chandrashekhar P. Pathak
  • Patent number: 11969527
    Abstract: Disclosed herein is a method of using a biomaterial for treating a condition. The biomaterial can comprise a plurality of geometric elements. Implantation of a biomaterial disclosed herein into a subject can treat, for example, cancer.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: April 30, 2024
    Assignee: BioSapien Inc.
    Inventor: Khatija Pinky Ali
  • Patent number: 11963942
    Abstract: A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: April 23, 2024
    Assignee: Health Hope Pharma Ltd
    Inventors: Denise S. B. Chan, Ming Tsung Lee, Weng Li Yoon, Johnson Yiu-Nam Lau
  • Patent number: 11957797
    Abstract: A chitosan film including ternary metal oxides. In an embodiment, the ternary metal oxides can include tungsten oxide nanoparticles (WO3 NPs), magnesium oxide nanoparticles (MgO NPs), and a graphene oxide (GO) layer. In an embodiment the chitosan film is porous. The chitosan film including ternary metal oxides can be used as a wound dressing for the clinical management of bacterially infected wounds.
    Type: Grant
    Filed: December 7, 2023
    Date of Patent: April 16, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mohamed Gouda, Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed
  • Patent number: 11951104
    Abstract: The present invention provides an aripiprazole sustained-release microsphere and a preparation method therefor. The microsphere comprises aripiprazole and polylactide-glycolide. The microsphere is of a spherical reticular skeleton structure, with reticular micropores distributed in the spherical surface, and aripiprazole filled in the micropores. The average particle diameter of the microsphere is less than 20 ?m, and is suitable for a 5 gauge needle. The content of aripiprazole is 65%-80% of the total weight of the microsphere.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: April 9, 2024
    Assignee: ZHUHAI LIVZON MICROSPHERE TECHNOLOGY CO. LTD.
    Inventors: Bin Chen, Xia Yin, Yanqing Wang, Peng Xu, Yuda Yang, Miaoli Chen, Weilun Ye, Linyan Lv, Huijuan Xu, Wenqi Lu, Xiangsheng Kong, Xiaoman Jiang
  • Patent number: 11951118
    Abstract: Provided is a method of making a preliposomal Annamycin lyophilizate, the composition made by the method, and the use of the composition made thereby in the treatment of cancer.
    Type: Grant
    Filed: October 5, 2023
    Date of Patent: April 9, 2024
    Assignees: Moleculin Biotech, Inc., Board of Regents, The University of Texas System
    Inventors: Donald Picker, Waldemar Priebe
  • Patent number: 11951125
    Abstract: One drug (solid preparation) 100 of the present invention is a drug for a disease of kidney that contains a silicon fine particle, an aggregate of the silicon fine particles, or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of the kidney disease.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: April 9, 2024
    Assignee: OSAKA UNIVERSITY
    Inventors: Hikaru Kobayashi, Yuki Kobayashi, Ryoichi Imamura, Norio Nonomura
  • Patent number: 11945788
    Abstract: The present disclosure relates to a process for preparing pitolisant hydrochloride of Formula-(I) and solid-state forms thereof.
    Type: Grant
    Filed: February 24, 2023
    Date of Patent: April 2, 2024
    Assignee: Nuray Chemicals Private Limited
    Inventors: Ramasamy Venkatragavan, Erugu Balaiah, Paramanandam Senthilkumaran, Guttha Jayaprasad, Manniyam Kailasam Selvam, Noti Krishnareddy, Sorakka Pichandi Parthipan, Murugan Arunkumar, Palaniswamy Premkumar, Salamuthu Kaliraj, Shanmugam Arumugam, Singavarapu Ajay Madhukar, Raman Silambarasan, Saminathan Karthick, Kudumudi Jayaraman Parthiban, Ravi Silambarasan
  • Patent number: 11944717
    Abstract: Disclosed are methods, devices and materials for the in situ formation of a nerve cap and/or a nerve wrap to inhibit neuroma formation following planned or traumatic nerve injury. The method includes the steps of identifying a severed end of a nerve, and positioning the severed end into a cavity defined by a form. A transformable media is introduced into the form cavity to surround the severed end. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the severed end. The media may be a hydrogel, and the transformation may produce a synthetic crosslinked hydrogel protective barrier. The media may include at least one anti-regeneration agent to inhibit nerve regrowth.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: April 2, 2024
    Assignees: Tulavi Therapeutics, Inc., Incept, LLC
    Inventors: Corinne Bright, Yong Ren, Kenneth M. Martin, Farhad Khosravi, Amarpreet S. Sawhney
  • Patent number: 11945723
    Abstract: Provided is a method of simply producing high-quality graphite oxide. The present invention relates to a method of producing a carbon material composite containing graphite oxide and at least one surfactant selected from the group consisting of a nonionic surfactant, a cationic surfactant, and an amphoteric surfactant, the method including: oxidizing graphite; mixing an aqueous dispersion obtained through the oxidizing, the aqueous dispersion containing graphite oxide dispersed therein, and the at least one surfactant selected from the group consisting of a nonionic surfactant, a cationic surfactant, and an amphoteric surfactant; and purifying the carbon material composite.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: April 2, 2024
    Assignee: Nippon Shokubai Co., Ltd.
    Inventors: Syun Gohda, Tatsuya Yamaguchi, Hironobu Ono, Osamu Konosu
  • Patent number: 11944721
    Abstract: A nerve conduit loaded with adipose-derived stem cells and a preparation method thereof are provided. The preparation method includes: S1, adding polycaprolactone and polyvinylpyrrolidone into a binary organic solvent, performing ultrasonic treatment, and then adding reduced graphene oxide nanoparticles to obtain a spinning solution; S2, electrospinning with the spinning solution and then washing for several times to obtain a semi-finished conduit product; and S3, injecting a cell mixture into the semi-finished conduit product to obtain the nerve conduit. A fiber surface of the nerve conduit has groove structures, and thus a specific surface area and cell adhesion sites are increased, and adhesion and proliferation of cells are facilitated.
    Type: Grant
    Filed: April 22, 2023
    Date of Patent: April 2, 2024
    Assignee: SHANGHAI SIXTH PEOPLE'S HOSPITAL
    Inventors: Yun Qian, Cunyi Fan, Xiangyun Yao, Zhiwen Yan, Lingchi Kong, Xu Wang
  • Patent number: 11930820
    Abstract: Silver nanoparticles made by a green synthesis method using silver nitrate and a chlorophyll derivative, such as a chlorophyllin are provided. The thus produced silver nanoparticles can have a crystalline structure and an average particle size ranging from about 10 nm to about 40 nm. The disclosed silver nanoparticles may be useful in treating, preventing, and/or reducing insect infestation of a variety of plants, particularly date palms.
    Type: Grant
    Filed: July 18, 2023
    Date of Patent: March 19, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Basem Mohamed Abdallah Abdelsalam, Enas Ali Abdelkader, Salaheldin Abdelraouf
  • Patent number: 11932606
    Abstract: This invention provides, among other things, compounds useful for treating diseases such as fibrosis and/or cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: March 19, 2024
    Assignee: The Regents of the University of California
    Inventors: David M. Jablons, Wei Xu, Liang You, Shu Liu, Shendong Yuan, Sunghoon Ma, Morrison Mac
  • Patent number: 11911476
    Abstract: The present invention relates to process for preparing a drug delivery composition comprising the steps of a) preparing a masterbatch comprising a drug and a first polymer by (i) extruding the first polymer, wherein said first polymer has a melting temperature below 140° C.; and (ii) introducing the drug during extrusion of the first polymer, with a drug content between 0.1% and 90%, based on the total weight of the masterbatch; and b) introducing the masterbatch in a polymer-based matrix during production of the drug delivery composition, wherein step a) is performed at a temperature at which the first polymer is in a partially or totally molten state, and step b) is performed at a temperature at which both the first polymer and at least a polymer of the polymer-based matrix are in a partially or totally molten state.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: February 27, 2024
    Assignee: PK MED
    Inventors: Philippe Pouletty, Frédérique Guillamot
  • Patent number: 11911400
    Abstract: Two vial containing kits containing aspirin for intravenous administration are disclosed. The first vial contains a lyophilized mixture of aspirin in crystalline form, a bulking agent such as mannitol and a surfactant. The second vial includes an aqueous diluent such as water for injection and a basifying agent such as Tris.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: February 27, 2024
    Assignee: RHOSHAN PHARMACEUTICALS, INC.
    Inventor: Nagesh R. Palepu
  • Patent number: 11911508
    Abstract: The present invention relates to: sustained-release microparticles capable of maintaining, for a long time, effects of preventing, treating or alleviating benign prostatic hyperplasia and prostate cancer and effects of preventing hair loss and promoting hair growth according to the administration of microparticles containing dutasteride; and a preparation method therefor, and according to the use of a method for administering the particles to a patient through an injection, a patient does not have to directly store or handle the microparticles, unlike an oral dosage form, and thus storage and handling are simple. In addition, drug effects are maintained for a long period of time of 1-3 months and, simultaneously, administration through injection can be facilitated since foreign body sensation and pain are reduced when being administered to a patient through injection because of the constant average diameter of the particles.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: February 27, 2024
    Assignee: INVENTAGE LAB INC.
    Inventors: Ju Hee Kim, Se Yeon Kim
  • Patent number: 11910795
    Abstract: This disclosure features herbicidal compositions including one or more indole auxins and methods of making and using the same.
    Type: Grant
    Filed: October 28, 2021
    Date of Patent: February 27, 2024
    Assignee: Suncor Energy Inc.
    Inventors: Jun Liu, Michael Fefer
  • Patent number: 11911350
    Abstract: A reduced coenzyme Q10-containing composition has high water solubility and excellent storage stability. A powder composition contains the reduced coenzyme Q10, starch octenylsuccinate, and gum Arabic. A method of producing the powder composition includes homogenizing the ingredients in water to obtain an emulsion composition; and drying the composition.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: February 27, 2024
    Assignee: Petroeuroasia Co., Ltd.
    Inventor: Hidehiro Takahashi
  • Patent number: 11911385
    Abstract: The present disclosure provides compositions of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), uveitis, macular edema, and uveitic macular edema.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: February 27, 2024
    Assignee: ALDEYRA THERAPEUTICS, INC.
    Inventors: Stephen Gitu Machatha, Dean Eliott, Tomasz Stryjewski